Roivant Sciences Ltd.

Roivant Sciences Ltd.

35.03
EUR
+0.12
(+0.33%)
-0.48EPS
23.39BMarket Cap
Feb 15Next Earn

Roivant Sciences Ltd. Documents

Q1 FY2026 · Press release

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients _ Roivant Sciences Ltd_ · September 3, 2025 · 5 pages

Read Roivant Sciences Ltd.'s results firsthand

Preview the first 2 pages of this press release
Create a free account to start reading

Full documents are included with Professional

Q1 FY2026 documents